| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/22/2001 | EP1124824A1 Chromenone and chromanone derivatives as integrin inhibitors |
| 08/22/2001 | EP1124822A1 Thrombin inhibitors |
| 08/22/2001 | EP1124821A1 Compounds |
| 08/22/2001 | EP1124820A1 Lipoic acid derivatives and their use in treatment of disease |
| 08/22/2001 | EP1124815A1 Method for producing luteolin and luteolin derivatives |
| 08/22/2001 | EP1124811A1 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 08/22/2001 | EP1124810A1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 08/22/2001 | EP1124809A1 Benzoylpyridazines |
| 08/22/2001 | EP1124806A2 Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mglur1 antagonists |
| 08/22/2001 | EP1124801A1 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 08/22/2001 | EP1124794A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 08/22/2001 | EP1124592A2 Textured and porous silicone rubber |
| 08/22/2001 | EP1124570A2 Novel neuropilin/growth factor binding and uses thereof |
| 08/22/2001 | EP1124568A1 Polyspecific binding molecules and uses thereof |
| 08/22/2001 | EP1124563A2 Methods and compositions for the prevention of tolerance to medications |
| 08/22/2001 | EP1124554A1 Pharmaceutical compositions containing tetrahydroisoquinoline compounds |
| 08/22/2001 | EP1124553A1 New use of glutamate antagonists for the treatment of cancer |
| 08/22/2001 | EP1124551A2 Delta 9 tetrahydrocannabinol (delta 9 thc) solution metered dose inhalers and methods of use |
| 08/22/2001 | EP1124548A2 Compositions for the treatment and prevention of cardiovascular diseases |
| 08/22/2001 | EP1124528A1 Multivalent macrolide antibiotics |
| 08/22/2001 | EP1124428A1 Stromal cell use |
| 08/22/2001 | EP1124418A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients |
| 08/22/2001 | EP1105518A4 USE OF mCRP FOR DELIVERY OF MATERIALS INTO CELLS |
| 08/22/2001 | EP1085811A4 Broad specificity dna damage endonuclease |
| 08/22/2001 | EP0777653B1 Dihygropyridine derivatives as bradykinin antagonists |
| 08/22/2001 | EP0697880B1 Inhibition of leukocyte adhesion |
| 08/22/2001 | CN1309663A Anti-angiogenic proteins and methods of use thereof |
| 08/22/2001 | CN1309660A Phosphinous and phosphonic acid derivs. used as medicaments |
| 08/22/2001 | CN1309657A Use of diazepins for preparing medicines for treating pathological conditions or diseases involving one of growth hormone release inhibiting factor receptors |
| 08/22/2001 | CN1309654A Biphenyl derivs. |
| 08/22/2001 | CN1309653A Polycyclic thiazolidin-2-ylidene amines, method for production and use thereof as medicaments |
| 08/22/2001 | CN1309649A Polyhydroalkylpyrazine derivs. and their preparation and medicines contg. them |
| 08/22/2001 | CN1309648A Piperazinone derivs. and their uses |
| 08/22/2001 | CN1309645A Biphenylsulfonyl-substd. imidazole derivs., their preparation process, their use as drug or diagnostic agent |
| 08/22/2001 | CN1309642A Novel 1,2,5-trisubstd. 1,2-dihydro-indazol-3-ones with anti-asthmatic, anti-allergic, anti-inflammatory, immuno-modulating and neuro-protective effects, method for production and use as medicam ent |
| 08/22/2001 | CN1309639A Pharmaceutical compositions comprising 2-quinolones |
| 08/22/2001 | CN1309638A N-substd. naphthalene carboxamides as neurokinin-receptor antagonists |
| 08/22/2001 | CN1309633A Diacylhydrazine derivs. as integrain inhibitors |
| 08/22/2001 | CN1309552A Pharmaceutical, hygienic and/or cosmetic compositions contg. sea water and uses |
| 08/22/2001 | CN1309184A Operation of enzymatic vitality of protoporphyrin primary oxidase in eukaryote |
| 08/22/2001 | CN1308944A Composition for peeling living toad and its usage |
| 08/22/2001 | CN1069833C Hand liniment |
| 08/22/2001 | CN1069829C Percutaneous applied medicine contg. gestodene |
| 08/21/2001 | US6278000 Growth-hormone secretagogues |
| 08/21/2001 | US6277989 Quinazoline derivatives as medicaments |
| 08/21/2001 | US6277987 Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives |
| 08/21/2001 | US6277985 As antibiotics; water solubility; in prodrugs |
| 08/21/2001 | US6277965 Amino acid sequence of cysteinyl trna (transfer ribonucleic acid) synthetase from chlamydia; bactericides; bacteriostats; enzyme inhibitors; drug screening; diagnosis; vaccines |
| 08/21/2001 | US6277884 Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
| 08/21/2001 | US6277882 Skin disorders |
| 08/21/2001 | US6277880 Chemical compounds |
| 08/21/2001 | US6277876 Antiinflammatory agents; prevent tissue degradation |
| 08/21/2001 | US6277875 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| 08/21/2001 | US6277869 Pharmaceutical composition |
| 08/21/2001 | US6277866 Alzheimer's disease |
| 08/21/2001 | US6277859 Highly selective kappa-opioid agonists useful as analgesics and diuretics with reduced physiological side effects |
| 08/21/2001 | US6277855 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| 08/21/2001 | US6277852 Piperazinyl 5-HT1 agonists and antagonists |
| 08/21/2001 | US6277851 Bicyclic amino-pyrazinone compounds |
| 08/21/2001 | US6277845 Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates |
| 08/21/2001 | US6277840 Antiinflammatory agents |
| 08/21/2001 | US6277839 Antiinflammatory agents, antipyretics, analgesics; side effect reduction |
| 08/21/2001 | US6277835 Method of tumor treatment |
| 08/21/2001 | US6277833 3-hydroxy-3-methyl-glutaryl coenzyme a (hgm--coa) reductase inhibitors which retard cholesterol biosynthesis |
| 08/21/2001 | US6277827 Stability makes the novel species suitable for milling, compression and improved bioavailability; 2s-(4-(2, 5-dioxopyrrolidin-1-yl)-2s-mercaptobutyrylamino)-4-methylpenta noic acid (2,2-dimethyl-1s-methylcarbamoylpropyl)amide |
| 08/21/2001 | US6277824 Enhancing or inhibiting cadherin-mediated functions comprising a his-ala-val sequence binding motif, an peptidomimetic or an antibody that binds to such a motif |
| 08/21/2001 | US6277822 Family of peptides known as xenoxins |
| 08/21/2001 | US6277813 Colostrum derived growth factor |
| 08/21/2001 | US6277620 Polypeptide for the prevention of bacterial infection; bactericides; for vaccine development |
| 08/21/2001 | US6277613 TRF1 binding protein, methods of use thereof |
| 08/21/2001 | US6277599 Monoclonal antiboby for the preferential killing of tumors; for diagnosis of cancer; for the treatment of cancer |
| 08/21/2001 | US6277594 Neurogenesis inducing gene |
| 08/21/2001 | US6277593 Generating preferential polypeptide; culture transformed cells, express preferential polypeptide, recover preferential polypeptide |
| 08/21/2001 | US6277410 Mixture comprises at least one block copolymer with ethylene(oxide) content of 50% or less, and at least one block copolymer with ethylene(oxide) content of 50% or more. |
| 08/21/2001 | US6277387 Use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF αantagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained |
| 08/21/2001 | US6277384 The amount of opioid antagonist included in the combination product provides at least a mildly negative, ?aversive? experience in physically dependent addicts (e.g., precipitated abstinence syndrome). |
| 08/21/2001 | US6277367 Erythropoietin solution preparation |
| 08/21/2001 | US6277154 Consisting of c12-c.14-fatty alcohol ethoxylate, oleic acid, ethanediol and/or 1.2-propanediol distearate glyceryl stearate and/or/at least one sugar fatty acid ester and one c.12-.18 -fatty alcohol |
| 08/21/2001 | US6277061 Method of inhibiting membrane-type matrix metalloproteinase |
| 08/21/2001 | CA2294595C Inhibiting bone resorption |
| 08/21/2001 | CA2207348C Benzimidazole derivatives |
| 08/21/2001 | CA2174315C Oligonucleotide modulation of multidrug resistance-associated protein |
| 08/21/2001 | CA2093793C Alkylidene analogs of 1'-aminospiro¬isoquinoline-4(1h),-3'-pyrrolidine|1,2',3,5'(2h)-tetrones useful as aldose reductase inhibitors |
| 08/21/2001 | CA2060652C N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives |
| 08/16/2001 | WO2001059130A2 Proteins producing an altered immunogenic response and methods of making and using the same |
| 08/16/2001 | WO2001059127A2 Drug metabolizing enzymes |
| 08/16/2001 | WO2001059120A2 Il-17 like molecules and uses thereof |
| 08/16/2001 | WO2001059103A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 08/16/2001 | WO2001059088A2 Vector |
| 08/16/2001 | WO2001059084A1 Protein c derivatives |
| 08/16/2001 | WO2001059071A2 Methods of preparing and using a viral vector library |
| 08/16/2001 | WO2001058954A2 Trade molecules and uses related thereto |
| 08/16/2001 | WO2001058951A2 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 08/16/2001 | WO2001058949A2 Heterologous polypeptide of the tnf family |
| 08/16/2001 | WO2001058921A2 Methods and compositions for generating angiostatin |
| 08/16/2001 | WO2001058918A2 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments |
| 08/16/2001 | WO2001058907A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058906A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058902A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058900A1 1h-imidazopyridine derivatives |